Project Grant R43AR077473

This $1,993,215 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research aimed at controlling thromboembolism (blood clots) after polytrauma (multiple traumatic injuries) using an RNA therapy against excess fibrinogen. The primary awardee, Versiti Wisconsin, Inc., a non-profit blood center and research organization, is conducting this research in collaboration with two sub-awardees: the University of North...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research aims to identify FDA-approved drugs that can stimulate lubricin production in human chondrocytes as a potential disease-modifying approach for post-traumatic osteoarthritis (PTOA). The $413,688 award to the University of Central Florida will support the development of a lubricin reporter cell system to screen...

This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $466,970.00 to Brigham & Women's Hospital Inc., a research institution affiliated with Harvard Medical School, to conduct research towards "ULTRA-LONG-TERM INTRA-ARTICULAR DELIVERY OF DISEASE-MODIFYING BIOLOGICS TO REDUCE THE PROGRESSION OF POSTTRAUMATIC OSTEOARTHRITIS." The award period is from February 15, 2025...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $549,437 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, effective September 1, 2024 through June 30, 2029, aims to develop a novel therapy that leverages the Hedgehog signaling pathway to improve tendon-to-bone...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Collamedix Inc. a $300,000 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to establish the feasibility of their "CollaLink" collagen-based scaffold for augmenting primary repair of anterior cruciate ligament (ACL) mid-substance tears. The project aims to demonstrate that the CollaLink scaffold, when placed around an ACL tear, can provide a...

This $556,160 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) aims to examine the efficacy of a rehabilitation approach called Rehabilitation with Exercise and Psychological Support (REPS) for patients who have undergone ACL reconstruction surgery. The REPS intervention integrates standard exercise rehabilitation with psychological support, including clinician training, patient education videos, and techniques like...

This $468,769 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research supports preclinical research to identify effective physical therapy and biological intervention strategies to reduce post-traumatic joint contracture (PTJC) following joint injury, particularly in the elbow. The key objectives are to: 1) Determine the optimal parameters of active...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of a novel, injectable cryoneurolysis treatment to reduce post-operative pain following total knee arthroplasty (TKA) surgery. The $998,787 award to Brixton Biosciences Inc. will be used to optimize a clinical use device that produces an injectable, biocompatible, and sterile ice slurry formulation to...

This $627,000 Project Grant from the US Department of Agriculture National Institute of Food and Agriculture's Agriculture and Food Research Initiative (AFRI) program (CFDA 10.310) will fund research at the University of Illinois from May 1, 2023 to April 30, 2026. The research aims to identify early gene and protein expression changes after equine joint injuries to further understanding of post-traumatic osteoarthritis (PTOA) development. Twelve horses will undergo controlled fetlock chip...